ESPR Q4 2021 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$15M+59.8% YoY

Gross Profit

$10M67.0% margin

Operating Income

-$56M-361.2% margin

Net Income

-$65M-422.8% margin

EPS (Diluted)

$-1.77

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$58M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$382M

Total Liabilities

$579M

Stockholders' Equity

-$197M

Cash & Equivalents

$209M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$10M	+59.8%
Gross Profit	$10M	$8M	+29.9%
Operating Income	-$56M	-$96M	+41.8%
Net Income	-$65M	-$104M	+37.7%

Revenue Segments

Product

$12M79%

Collaboration Revenue

$3M21%